First scientific presentation of detailed PK data demonstrates dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing Detailed data reinforces previously reported topline results demonstrating that GlyphAgo achieved a
Trial is designed to demonstrate proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep and anxiety symptoms in patients with generalized anxiety disorder In Phase 1, GlyphAgo demonstrated a statistically significant 6.8-fold increase in bioavailability compared to unmodified
BOSTON --(BUSINESS WIRE)--Sep. 14, 2026-- Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series
Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosing Key secondary endpoint also met, showing a single evening dose of 250 mg GlyphAllo did not impair
BOSTON --(BUSINESS WIRE)--Aug. 31, 2026-- Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the
Enrollment in Phase 2b BUOY-1 trial of GlyphAllo ™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026 Following positive data from completed Phase 1 proof-of-concept trial of
New data from Phase 1 trial of GlyphAgo TM build upon previously reported topline data and further demonstrate GlyphAgo TM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing Enrollment in
Repeat dosing of GlyphAgo confirms favorable safety, tolerability, and pharmacokinetics observed across the Phase 1 program, with no liver-related adverse events observed New data demonstrate seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid
BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the
BOSTON --(BUSINESS WIRE)--Apr. 30, 2026-- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of its upsized initial public offering of 14,160,000
